beta

ALLO

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Market Cap:

Primary Exchange:

Website: /stocks/allo

Shares Outstanding:

Float:

Dividend: (%)

Beta:

Sector:

Industry:

Short Interest ():

Ethical Flags

Longest drawdown: 21 trading days

From: 2018-11-06 To: 2018-12-07

Lowest Point:

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Looking Beyond The Election (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-04 06:30:58:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Stocks To Watch: Looking Beyond The Election

via: SeekingAlpha at 2018-11-03 09:26:43:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Yep, there is an election next week that's going to steal some headlines, but inves… read more...

Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting

via: Business Wire at 2018-11-01 09:26:00:000

Data Provide Insights in Preparation for Investigational New Drug (IND) Submissions Planned in 2019 for ALLO-501 (anti-CD19) in Non-Hodgkin Lymphoma and ALLO-715 (anti-BCMA) in Multiple Myeloma Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pionee… read more...

Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting

via: Business Wire at 2018-11-01 09:26:00:000

Data Provide Insights in Preparation for Investigational New Drug (IND) Submissions Planned in 2019 for ALLO-501 (anti-CD19) in Non-Hodgkin Lymphoma and ALLO-715 (anti-BCMA) in Multiple Myeloma Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pionee… read more...

Biotech IPOs on pace for near-record year - WSJ

via: SeekingAlpha at 2018-10-31 09:03:50:000

The Wall Street Journal reports that the pace of biotech IPOs in on track for a near-record year, although many are riskier due to being in earlier stages of development. The public funding rush has been heavily influenced by the FDA's willingness to accelerate approval for promising drugs… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector

via: SeekingAlpha at 2018-10-27 08:44:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are being put to the rest with major indexes now down sharply on the year… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Allogene closes $373M IPO

via: SeekingAlpha at 2018-10-15 16:47:01:000

Allogene Therapeutics (NASDAQ: ALLO ) has closed its IPO of 20.7M shares of common stock at $18 per share including the full exercise of underwriters' over-allotment of 2.7M shares. More news on: Allogene Therapeutics, Healthcare stocks news, IPO News, Read more … read more...

Allogene closes $373M IPO

via: SeekingAlpha at 2018-10-15 16:47:01:000

Allogene Therapeutics (NASDAQ: ALLO ) has closed its IPO of 20.7M shares of common stock at $18 per share including the full exercise of underwriters' over-allotment of 2.7M shares. More news on: Allogene Therapeutics, Healthcare stocks news, IPO News, Read more … read more...

Allogene closes $373M IPO

via: SeekingAlpha at 2018-10-15 16:47:01:000

Allogene Therapeutics (NASDAQ: ALLO ) has closed its IPO of 20.7M shares of common stock at $18 per share including the full exercise of underwriters' over-allotment of 2.7M shares. More news on: Allogene Therapeutics, Healthcare stocks news, IPO News, Read more … read more...

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-10-15 16:30:00:000

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock… read more...

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-10-15 16:30:00:000

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock… read more...

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-10-15 16:30:00:000

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock… read more...

U.S. IPO Weekly Recap: Despite Sell-Off, 4 IPOs Price With Unicorn Anaplan Up 43%

via: SeekingAlpha at 2018-10-14 09:31:41:000

The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or below issue. One small SPAC priced. Anaplan priced $2 above the range and… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX